-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Traumatic brain injury (TBI) is the main cause of death and disability in trauma patients.
study found that early use of methylacyclic acid may be beneficial in patients with TBI.
recently examined the effects of out-of-hospital treatment with aminocyclic acid on neurological outcomes in patients with moderate to severe TBI within 2 hours of trauma.
study was conducted at 59 emergency trauma centres in the United States and Canada, aged 15 and over, involving TBI patients with a systolic score of 12 or less and systolic pressure of 90mmHg or more in Glasgow, receiving 1g of methamphetamine and 1g of in-hospital injection 2 hours after injury Intra-hospital acetate therapy (in-hospital acetate group, n=312), in-hospital injection of 2g of amino acid and in-hospital placebo therapy (in-hospital treatment group, n=345) and in-hospital placebo therapy (placebo group; n=309). The main endpoint of the
study was a good six-month neurologic assessment (i.e., a Glasgow prognosis score of 4) and included five secondary endpoints, including a 28-day mortality rate, a six-month disability score, intracranial haemorrhage, epilepsy and thrombosis.
966 patients, with an average age of 42 years and 255 (74 per cent) men, had an average of 8 out of 8 in Glasgow and 819 (84.8 per cent) completed six months of follow-up.
65 percent of patients in the methamphetamine group had a good neurosurgery assessment at 6 months, and 62 percent in the placebo group (a difference of 3.5 percent).
6-month disability assessment scale in the acetate group was 6.8 and 7.6 in the placebo group.
of intracranial bleeding in the acetate group was 16% and in the placebo group was 20%.
28-day mortality rate was 14 per cent in the methamphetamine group and 17 per cent in the placebo group.
6-month disability score or intracranial bleeding rate between the two groups.
study found that, based on the Glasgow coma score, there was no significant improvement in the nervous system prognostics of patients with moderate to severe trauma brain injury who received treatment for amino acid outside the hospital.
.
